Literature DB >> 1831251

Pulmonary endometriosis: conservative treatment with GnRH agonists.

J Espaulella1, J Armengol, F Bella, J M Lain, J Calaf.   

Abstract

The lung is an infrequent location of extragenital endometriosis, an exceptional cause of hemoptysis or pneumothorax. Adequate management has not yet been well established. We present two cases of pulmonary endometriosis, parenchymal and pleural. The presenting symptoms were catamenial hemoptysis and pneumothorax, respectively, which were treated with GnRH analogues. The first patient received Buserelin (900 micrograms/day intranasally) for 6 months. After 15 months of normal menstrual activity, the symptoms reappeared. The patient was then treated with Triptorelin (3.75 mg/month intramuscularly) for 6 months and remains asymptomatic and menstruating 14 months after discontinuing treatment. The patient presenting with pneumothorax was treated with leuprolide (1 mg/day subcutaneously) for 6 months and is asymptomatic 1 year after stopping treatment. These results suggest that GnRH analogues may be an acceptable alternative to danazol in the medical management of pulmonary endometriosis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1831251

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  3 in total

1.  Bronchoscopic and angiographic findings in tracheobronchial endometriosis.

Authors:  P H Kuo; H C Wang; Y S Liaw; S H Kuo
Journal:  Thorax       Date:  1996-10       Impact factor: 9.139

Review 2.  Leuprorelin. A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders.

Authors:  G L Plosker; R N Brogden
Journal:  Drugs       Date:  1994-12       Impact factor: 9.546

Review 3.  Gonadotrophin-releasing hormone agonists. A guide to use and selection.

Authors:  M Filicori
Journal:  Drugs       Date:  1994-07       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.